Dr. Terri Lee is responsible for investment identification, due diligence and business development activities at MPM.
Recently awarded her Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco, Terri’s thesis focused on the role of actin nucleators in DNA repair pathways. In addition to academic research, Terri worked on identifying commercial opportunities and company formation at the Gladstone Institutes, including taking on an operations role at a therapeutics company in the neurodegenerative space.
Terri received her B.S. in Pharmacology and Microbiology from the University of California, Santa Barbara.
Dr. Geraldine Paulus is responsible for investment identification, due diligence, business development and new company creation activities at MPM.
Prior to joining MPM, Geraldine served as the Director of Research and Analytics at The Engine, leading technical and IP diligence, competitive landscape analysis and product/market research in support of the investment team as well as portfolio companies. She brings over a decade of academic experience, with a strong focus on translational and cross-disciplinary research in chemical engineering and biology. During her Ph.D. studies in Dr. Michael Strano’s lab (MIT) she developed novel applications for nanomaterials, ranging from nanoelectronics to biosensors. As a postdoctoral researcher, she worked in the lab of Dr. Ramnik Xavier (MGH, The Broad Institute) implementing CRISPR technology to elucidate gene functions in (auto)immune disorders. Geraldine has interned at the Partners Innovation Fund and consulted for an early-stage Flagship Pioneering-backed company.
Geraldine holds B.S. and M.S. degrees in Chemical Engineering from the KU Leuven (Belgium) and a Ph.D. in Chemical Engineering from MIT.
Kellie Neville is the Director of Investor Relations at MPM Capital. She joins MPM’s Managing Directors in building lasting relationships with its Limited Partners. Kellie also leads MPM’s communications and marketing efforts.
Prior to joining MPM, Kellie was Director of Investor Relations & Marketing at 424 Capital, a boutique private equity investor, where she was responsible for raising capital, investor relationships and product development. Prior to that, Kellie was a Senior Investor Relations Associate at TA Associates, a middle market growth equity partner, supporting the firm’s fundraising efforts and ongoing Limited Partner relationships.
Kellie earned her B.A. in Public Relations and Marketing Communications from Simmons University.
Nicholas McGrath is the General Counsel and Chief Compliance Officer at MPM Capital. His primary responsibility is to oversee the firm’s legal and compliance program.
Prior to joining MPM, Nick served as the General Counsel and Chief Compliance Officer at a Boston-based healthcare and biotech investment adviser, where he was responsible for managing the legal, regulatory, and compliance functions at the firm. Additionally, Nick was a corporate associate for two law firms in the Boston area.
Nick obtained his J.D. from the University of Maine School of Law, and an LL.M. from St. John’s University School of Law. He holds a B.A. in International Business from the University of Massachusetts, Amherst. Nick is also a FINRA Certified Regulatory and Compliance Professional.
Dr. Brian Goodman is responsible for investment identification, due diligence, business development and new company creation activities at MPM. Brian is a board observer for Orna Therapeutics, Triplet Therapeutics, and HotKnot Therapeutics and a co-founder of HotKnot Therapeutics. Brian also serves interim roles at Orna Therapeutics in Business Development and at Hotknot Therapeutics in Corporate Development.
Prior to joining MPM, Brian co-founded Evelo Biosciences (EVLO) and served as Head of Technology and Innovation. At Evelo, Brian led a team that established new programs to discover, formulate, and evaluate the pharmacology of microbial drugs across multiple therapeutic areas. He contributed to the in-licensing of foundational IP and forged collaborative research with multiple academic groups to complement Evelo’s internal research and development efforts. He is an inventor on multiple patent applications. Before taking the operational role at Evelo, Brian was a Senior Associate at Flagship Pioneering where he worked with the entrepreneurial division to build and launch new biotech ventures.
Brian holds a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School, and B.S. and B.A. degrees in biochemistry and economics, respectively, from Brandeis University.
Dr. Devin Quinlan is responsible for investment identification, due diligence, business development, and company creation activities at MPM. Devin joined MPM full time in 2018 after completing an internship with the firm, and has since supported multiple investments across diverse therapeutic areas, including MPM’s investments into Orna Therapeutics and Triplet Therapeutics. Devin was also part of the founding team of a stealth oncology NewCo, where he is Head of Strategy & Operations and a Board Observer.
Prior to joining MPM, Devin completed his Ph.D. in Biological Engineering at the Massachusetts Institute of Technology (MIT) under advisor Ram Sasisekharan. His thesis was focused on uncovering structure-function relationships of antibodies which target viral antigens, including Ebola and Zika viruses. In addition to his academic research, Devin served as part of the inaugural leadership team of the MIT Biotech Group, which has since grown into the largest life-sciences student organization at MIT.
Devin received his B.S. in Bioengineering from the University of California, Los Angeles.
Dr. Stephen (Steve) Curtis is responsible for investment identification, due diligence and business development activities at MPM, and oversees MPM’s investment collaboration with Dana-Farber Cancer Institute. Steve brings to his role experience in early-stage, start-up creation and strategic deal structuring and negotiation in the biotech and pharmaceutical industries. Steve supports MPM’s partnership with Gilead Sciences.
Prior to joining MPM, Steve was Senior Director of Business Development – Emerging Technology and Innovation for Eli Lilly and Company, out of Lilly’s external research hub in Cambridge, MA. In that role, he focused on Lilly’s strategic limited partnerships in top-tier venture funds, direct equity investments in selected biotechnology companies, “build-to-buy” investments and other “shared-risk” drug discovery and early development relationships. Prior to Lilly, Steve co-led the Bioscience Ventures group within 2M Companies, the Dallas-based family office of Morton H. Meyerson, focusing on Seed and Series A biotech investments and portfolio management. Before 2M, he worked at Reata Pharmaceuticals, entering through their Biotechnology Leadership Development program and ultimately running the Technology Evaluation and In-Licensing program. Steve also interned at Siemens Venture Capital in Boston while finishing his graduate studies.
Steve completed the competitive, two-year venture capital Kauffman Fellows training program. He earned his Ph.D. in Biological and Biomedical Sciences at Harvard Medical School and a dual B.S. degree, summa cum laude, in Molecular Biology and Applied Economics and Management from Cornell University.
Kristen Laguerre, an accomplished operating executive, is a Managing Director, Chief Financial Officer and Chief Operating Officer at MPM Capital. With over 20 years of financial leadership and management experience in the venture capital industry her primary responsibility is to oversee the firm’s finance and administrative functions. Kristen is also an investment committee member of the UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both private and public equities) managed by MPM. Kristen was previously CFO at Cullinan Oncology, an MPM portfolio company.
Prior to joining MPM, Kristen served as Partner and CFO at Flare Capital Partners, and, previously, Partner and CFO at Atlas Venture, an early-stage life sciences and technology venture capital firm, where she was responsible for finance, operations and administration. Before Atlas Venture, she was Vice President – Finance at Softbank Capital, where she was responsible for finance, human resources and operations associated with both Softbank’s venture funds and its global activities outside of East Asia. Earlier in her career, Kristen spent seven years with Arthur Andersen LLP.
Widely recognized in the industry, Kristen is a board member of Financial Executives Alliance, a steering committee member of Women in Alternative Assets and previously served as a board member of the Private Equity CFO Association.
Kristen earned her M.B.A. in Finance and Accounting from Boston University and her B.A. in Economics from Wesleyan University.
Ed Hurwitz, an accomplished biotech executive and investor, is a Managing Director at MPM Capital. Ed serves as Chairman of MPM portfolio companies BioIntervene and Rekindle Therapeutics and is on the board of Dyne Therapeutics (NASDAQ: DYN).
Prior to MPM, he was founder and Managing Director of Precision BioVentures where he founded and seeded start-up biotechnology companies, including Viewpoint Therapeutics. As a Director at Alta Partners, he led 12 successful investments including Applied Genetic Technologies Corporation, Avid Radiopharmaceuticals (acquired by Lilly), Calistoga Pharmaceuticals (acquired by Gilead), Cara Therapeutics, FoldRx Pharmaceuticals (acquired by Pfizer), MacroGenics and Taligen Therapeutics (acquired by Alexion).
Over the course of his career, he has been a Senior Vice President and CFO of Affymetrix, a microarray pioneer, and a biotech research analyst for Robertson Stephens & Company and Smith Barney Shearson. He also practiced law at Cooley Godward LLP.
Ed earned his J.D. and M.B.A. degrees from the University of California, Berkeley’s Boalt School of Law and Haas School of Business, and his B.A. in Molecular Biology from Cornell University.
Dr. Shinichiro (Shin) Fuse, an experienced biotech investor, is a Managing Director at MPM Capital and an investment committee member of the UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both private and public equities) managed by MPM. Shin also supports MPM’s relationship with Astellas and is a Board Member of iOmx, Orna Therapeutics and Triplet Therapeutics. Shin serves as a board observer for CODA Biotherapeutics, and recently in operational roles at MPM portfolio companies as the interim CEO of Orna Therapeutics and interim SVP of Business Development at ElevateBio.
Prior to joining MPM, he was Director of Business Development at bluebird bio, where he was instrumental in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy and genome editing, including partnerships with Five Prime Therapeutics, National Cancer Institute and the acquisition of Pregenen. Previously, he was at Campbell Alliance (Syneos Health) as a life science strategy consultant, and at PureTech Ventures, where he was a member of the founding team of Vedanta Biosciences. He also serves as a columnist for Nikkei Biotech, the leading biotech journal in Japan.
Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, an M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.